Low-grade gliomas (LGGs) are rarely diagnosed as an incidental, asymptomatic finding, and it is not known how the early surgical management of these tumors might affect outcome. The purpose of this study was to compare the outcomes of patients with incidental and symptomatic LGGs and determine any prognostic factors associated with those outcomes.
All patients treated by the lead author for an LGG incidentally discovered between 1999 and 2010 were retrospectively reviewed. “Incidental” was defined as a finding on imaging that was obtained for a reason not attributable to the glioma, such as trauma or headache. Primary outcomes included overall survival, progression-free survival (PFS), and malignant PFS. Patients with incidental LGGs were compared with a previously reported cohort of patients with symptomatic gliomas.
Thirty-five patients with incidental LGGs were identified. The most common reasons for head imaging were headache not associated with mass effect (31.4%) and trauma (20%). Patients with incidental lesions had significantly lower preoperative tumor volumes than those with symptomatic lesions (20.2 vs 53.9 cm3, p < 0.001), were less likely to have tumors in eloquent locations (14.3% vs 61.9%, p < 0.001), and had a higher prevalence of females (57.1% vs 36%, p = 0.02). In addition, patients with incidental lesions were also more likely to undergo gross-total resection (60% vs 31.5%, p = 0.001) and had improved overall survival on Kaplan-Meier analysis (p = 0.039, Mantel-Cox test). Progression and malignant progression rates did not differ between the 2 groups. Univariate analysis identified pre- and postoperative volumes as well as the use of motor or language mapping as significant prognostic factors for PFS.
In this retrospective cohort of surgically managed LGGs, incidentally discovered lesions were associated with improved patient survival as compared with symptomatic LGGs, with acceptable surgical risks.
Abbreviations used in this paper: KPS = Karnofsky Performance Scale; LGG = low-grade glioma; MPFS = malignant progression-free survival; OS = overall survival; PFS = progression-free survival; SMA = supplementary motor area; 18F-FET = fluorine-18–labeled fluoroethyl-l-tyrosine.
Central Brain Tumor Registry of the United States: CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004–2005(http://www.cbtrus.org/reports/2009-NPCR-04-05/CBTRUS-NPCR2004-2005-Report-.pdf) [Accessed September 19 2011]
ChangEFClarkAJensenRLBernsteinMGuhaACarrabbaG: Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. Clinical article. J Neurosurg111:203–2102009
LangloisJARutland-BrownWThomasKE: Traumatic Brain Injury in the United States: Emergency Department Visits Hospitalizations and DeathsAtlantaCenters for Disease Control and Prevention, National Center for Injury Prevention and Control2006. (http://www.cdc.gov/ncipc/pub-res/tbi_in_us_04/tbi%20in%20the%20us_jan_2006.pdf) [Accessed September 19 2011]
SmithJSChaSMayoMCMcDermottMWParsaATChangSM: Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. J Neurosurg103:428–4382005
YueNCLongstrethWTJrElsterADJungreisCAO'LearyDHPoirierVC: Clinically serious abnormalities found incidentally at MR imaging of the brain: data from the Cardiovascular Health Study. Radiology202:41–461997